ARIAD Pharmaceuticals (ARIA) Full Iclusig Approval, Label Update Incremental Positive - Leerink
Tweet Send to a Friend
Leerink Partners analyst Michael Schmidt reiterated an Outperform rating and $20 price target on ARIAD Pharmaceuticals (NASDAQ: ARIA) after the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE